Financial Counselors Inc. Acquires 668 Shares of Danaher Co. (NYSE:DHR)

Financial Counselors Inc. boosted its holdings in Danaher Co. (NYSE:DHR) by 0.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 111,219 shares of the conglomerate’s stock after acquiring an additional 668 shares during the quarter. Financial Counselors Inc.’s holdings in Danaher were worth $30,921,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in Danaher in the 2nd quarter worth approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the 3rd quarter worth $40,000. MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the 2nd quarter valued at $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher during the 2nd quarter worth $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on DHR. Raymond James reduced their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Wells Fargo & Company started coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. UBS Group cut their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Price Performance

DHR stock opened at $238.90 on Thursday. The firm has a 50-day moving average of $256.00 and a 200 day moving average of $259.66. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market cap of $172.55 billion, a P/E ratio of 45.59, a PEG ratio of 4.37 and a beta of 0.85. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 EPS. On average, sell-side analysts forecast that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.